The German Society of Urology (Deutsche Gesellschaft für Urology, DGU) has highlighted Acousia’s PROHEAR Study as their Study of the Month, acknowledging the urgent need for effective prevention of cisplatin-induced hearing loss in testicular cancer treatment.
PROHEAR Study highlighted as ‘Study of the Month’ by German Society of Urology
- Tübingen, Germany, July 4, 2025
Share this release
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
About Acousia Therapeutics GmbH
Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. The unique dual mode of action of its small-molecule Kv7.4 activators combines acute functional OHC enhancement and sustained OHC protection and aims to both enhance and preserve a patient’s natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.